A new perspective on metformin therapy in type 1 diabetes (original) (raw)
Livingstone, Rachel 
ORCID: https://orcid.org/0000-0003-0950-5016, Boyle, James G. and Petrie, John R. ORCID: https://orcid.org/0000-0002-4894-9819(2017) A new perspective on metformin therapy in type 1 diabetes.Diabetologia, 60(9), pp. 1594-1600. (doi: 10.1007/s00125-017-4364-6) (PMID:28770327)
Abstract
Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Boyle, Dr James and Livingstone, Dr Rachel and Petrie, Professor John |
| Authors: | Livingstone, R., Boyle, J. G., and Petrie, J. R. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Diabetologia |
| Publisher: | Springer |
| ISSN: | 0012-186X |
| ISSN (Online): | 1432-0428 |
| Published Online: | 02 August 2017 |
| Copyright Holders: | Copyright © 2017 The Authors |
| First Published: | First published in Diabetologia 60(9):1594-1600 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record